Trial reportEuropean journal of nuclear medicine and molecular imaging2013
Regional distribution and kinetics of [18F]fluciclovine (anti-[18F]FACBC), a tracer of amino acid transport, in subjects with primary prostate cancer.
Trial report in European journal of nuclear medicine and molecular imaging, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 3 syntheses or guidelines pooled it, 95 citations in OpenAlex.
- Comparative Detection Performance of PSMA and Non-PSMA PET Tracers in Recurrent and Primary Prostate Cancer: A Systematic Review and Network Meta-Analysis.Clinical nuclear medicine · 2026Pooled it
- [European journal of nuclear medicine and molecular imaging · 2020Guideline
- Diagnostic Performance of PET/CT Using 18F-FACBC in Prostate Cancer: A Meta-Analysis.Frontiers in oncology · 2019Pooled it
- AnCurrent radiopharmaceuticals · 2024Trial
- [European journal of nuclear medicine and molecular imaging · 2021Trial
- Prediction of prostate cancer aggressiveness usingScientific reports · 2020Trial
- A PET/MRI study towards finding the optimal [European journal of nuclear medicine and molecular imaging · 2017Trial
- (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial.European journal of nuclear medicine and molecular imaging · 2016Trial
- Metabolic Imaging and Molecular Signatures Reveal Metabolic Phenotypes in Recurrent Glioblastoma.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Preclinical Comparison ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Physiological biodistribution ofFrontiers in nuclear medicine · 2026Article
- Article
- Glioblastoma PET/MRI: kinetic investigation of [European journal of nuclear medicine and molecular imaging · 2023Article
- Dual contribution of the mTOR pathway and of the metabolism of amino acids in prostate cancer.Cellular oncology (Dordrecht, Netherlands) · 2022Review
- Tracers progress for positron emission tomography imaging of glial-related disease.Journal of biomedical research · 2022Article
- Principles of Tracer Kinetic Analysis in Oncology, Part II: Examples and Future Directions.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- The Role of [Cancers · 2021Article
- The chemical tool-kit for molecular imaging with radionuclides in the age of targeted and immune therapy.Cancer imaging : the official publication of the International Cancer Imaging Society · 2021Review
- Review
- Amino acid transporter expression and 18F-FACBC uptake at PET in primary prostate cancer.American journal of nuclear medicine and molecular imaging · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose[(18)F]Fluciclovine (anti-[(18)F]FACBC) is a synthetic amino acid developed for PET assessment of the anabolic component of tumour metabolism in clinical routine. This phase 1 trial evaluated the safety, tracer stability and uptake kinetics of [(18)F]fluciclovine in patients.
methodsSix patients with biopsy-proven prostate cancer were investigated with 3-T MRI and PET/CT. All underwent dynamic [(18)F]fluciclovine PET/CT of the pelvic area for up to 120 min after injection of 418 ± 10 MBq of tracer with simultaneous blood sampling of radioactivity. The kinetics of uptake in tumours and normal tissues were evaluated using standardized uptake values (SUVs) and compartmental modelling.
resultsTumour deposits as defined by MRI were clearly visualized by PET. Urine excretion was minimal and normal tissue background was low. Uptake of [(18)F]fluciclovine in tumour from the blood was rapid and the tumour-to-normal tissue contrast was highest between 1 and 15 min after injection with a 65 % reduction in mean tumour uptake at 90 min after injection. A one-compartment model fitted the tracer kinetics well. Early SUVs correlated well with both the influx rate constant (K (1)) and the volume of distribution of the tracer (V (T)). There were no signs of tracer metabolite formation. The product was well tolerated in all patients without significant adverse events.
conclusion[(18)F]Fluciclovine shows high uptake in prostate cancer deposits and appears safe for use in humans. The production is robust and the formulation stable in vivo. An early imaging window seems to provide the best visual results. SUV measurements capture most of the kinetic information that can be obtained from more advanced models, potentially simplifying quantification in future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.